Table 2 Amino acid substitutions, antifungal agent MICs, and patient’s characteristics for 22 Candida tropicalis clinical isolates
Designation | Origin | Date of isolation | Age /Sex | Underlying disease | Ward | Substitution of amino acid residue (Erg11p) | DST | Antifungal agent MIC (mg/L) | Previous azole usea | Antifungal therapy | Thirty-day outcome | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FLU | VOR | ITR | POS | AMB | 5FC | |||||||||||
Ct01R | Blood | 8/5/15 | 37/M | ALL | Hematology | Y132F, S154F | 225 | 128 | 4 | 0.25 | 0.25 | 0.5 | ≤0.06 | FLU, VOR | CAS, AMB | Survival |
Ct02R | Pleural fluid | 10/4/14 | 65/M | Liver Transplantation | ICU | None | 639 | 8 | 0.5 | 0.25 | 0.25 | 0.5 | ≤0.06 | VOR | None | Death |
Ct03R | Blood | 9/12/13 | 72/F | Chronic Renal Failure | Gastroenterological Surgery | Y132F, S154F | 639 | 256 | 4 | 0.5 | 0.5 | 0.5 | 0.25 | None | FLU, AMB | Death |
Ct04R | Blood | 11/8/13 | 26/M | ALL | Hematology | Y132F, S154F | 329 | 64 | 2 | 0.25 | 0.25 | 0.5 | ≤0.06 | FLU | ITR | Survival |
Ct05R | Blood | 2/22/15 | 40/M | CML | Hematology | Y132F, S154F | 615 | 128 | 4 | 0.25 | 0.5 | 0.5 | 0.12 | FLU, ITR | CAS | Survival |
Ct06R | Blood | 4/6/17 | 38/M | AML | Hematology | Y132F, S154F | NT | 128 | 4 | 0.5 | 0.5 | 0.5 | 0.12 | FLU, VOR | CAS, AMB | Survival |
Ct07R | Urine | 9/15/14 | 87/F | Cholangitis | ICU | Y132F, S154F | 225 | 256 | > 8 | 1 | 1 | 0.5 | ≤0.06 | None | None | Survival |
Ct08R | Urine | 7/22/15 | 19/M | Nephrlithotomy | Urology | Y132F, S154F | 225 | 64 | 4 | 0.5 | 1 | 1 | ≤0.06 | None | VOR | Survival |
Ct09R | Urine | 8/7/15 | 64/M | Pneumonia | Respiratory | Y132F, S154F | 225 | > 256 | 8 | 1 | 1 | 1 | ≤0.06 | None | None | Survival |
Ct10R | Blood | 9/2/15 | 25/F | ALL | Hematology | Y132F, S154F | 506 | > 256 | 8 | 1 | 1 | 1 | ≤0.06 | ITR | CAS | Survival |
Ct11R | Urine | 9/26/15 | 80/M | Pneumonia | ICU | Y132F, S154F | 508 | 64 | 2 | 0.25 | 0.25 | 0.5 | ≤0.06 | None | None | Death |
Ct12R | Urine | 6/17/15 | 83/F | Adrenocortical Carcinoma | ICU | Y132F, S154F | 508 | 64 | 4 | 0.25 | 0.25 | 0.5 | ≤0.06 | None | None | Death |
Ct01S | Cervix | 4/5/17 | 34/F | Premature Delivery | Obstetrics | None | NT | 2 | 0.12 | 0.12 | 0.12 | 0.25 | ≤0.06 | None | None | Survival |
Ct02S | Sputum | 6/15/17 | 62/M | Respiratory Failure | Respiratory | None | NT | 1 | 0.12 | 0.12 | 0.12 | 0.25 | ≤0.06 | None | None | Survival |
Ct03S | Urine | 6/23/17 | 16/F | Ewing’s Sarcoma | Musculoskeletal Tumor | None | NT | 1 | 0.06 | 0.12 | 0.12 | 0.25 | 0.12 | None | FLU | Survival |
Ct04S | Catheter | 6/26/17 | 44/M | Hepatocellular Carcinoma | ICU | None | NT | 2 | 0.12 | 0.25 | 0.25 | 0.25 | ≤0.06 | None | None | Death |
Ct05S | Blood | 11/27/14 | 50/M | Cirrhosis | Hepatology | None | 519 | 2 | 0.12 | 0.25 | 0.25 | 1 | ≤0.06 | None | CAS | Survival |
Ct06S | Blood | 2/13/15 | 43/M | AML | Hematology | None | 169 | 1 | 0.12 | 0.25 | 0.5 | 0.5 | ≤0.06 | None | ITR | Death |
Ct07S | Urine | 7/3/15 | 80/M | CHD | Cardiology | None | 343 | 1 | 0.12 | 0.25 | 0.25 | 0.5 | 0.25 | None | None | Survival |
Ct08S | Blood | 9/25/15 | 42/M | AML | Hematology | None | 399 | 1 | 0.12 | 0.25 | 0.12 | 1 | 0.12 | None | VOR, AMB | Death |
Ct09S | Blood | 10/31/14 | 51/F | AML | Hematology | None | 300 | 2 | 0.25 | 0.25 | 0.25 | 0.5 | 0.12 | None | VOR, AMB | Death |
Ct10S | Urine | 7/26/17 | 23/M | HPS | ICU | None | 169 | 1 | 0.12 | 0.25 | 0.25 | 0.5 | ≤0.06 | None | None | Survival |